🚀 VC round data is live in beta, check it out!
Tonix Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Tonix Pharmaceuticals and similar public comparables like Cartesian Therapeutics, EQL Pharma, Sagimet Biosciences, BioVersys and more.
Tonix Pharmaceuticals Overview
About Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp is a commercial-stage biotechnology company focused on the development and commercialization of treatments for central nervous system (CNS) disorders and immunological conditions. Its product portfolio includes TONMYA (cyclobenzaprine HCl sublingual tablets 2.8 mg), an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
Founded
2007
HQ
Employees
81
Website
Sectors
Financials (LTM)
Market Cap
$179M
Tonix Pharmaceuticals Financials
Tonix Pharmaceuticals reported last 12-month revenue of $23M.
In the same LTM period, Tonix Pharmaceuticals generated $15M in gross profit and had net loss of ($120M).
Revenue (LTM)
Tonix Pharmaceuticals P&L
In the most recent fiscal year, Tonix Pharmaceuticals reported revenue of $10M and EBITDA of ($72M).
Tonix Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $23M | XXX | $10M | XXX | XXX | XXX |
| Gross Profit | $15M | XXX | $2M | XXX | XXX | XXX |
| Gross Margin | 64% | XXX | 23% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($72M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (711%) | XXX | XXX | XXX |
| EBIT Margin | (526%) | XXX | (745%) | XXX | XXX | XXX |
| Net Profit | ($120M) | XXX | ($130M) | XXX | XXX | XXX |
| Net Margin | (517%) | XXX | (1288%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Tonix Pharmaceuticals Stock Performance
Tonix Pharmaceuticals has current market cap of $179M.
Market Cap Evolution
Tonix Pharmaceuticals' stock price is $13.97.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| $179M | 0.0% | XXX | XXX | XXX | $-10.17 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTonix Pharmaceuticals Valuation Multiples
Tonix Pharmaceuticals trades at (0.5x) EV/Revenue multiple, and 0.2x EV/EBITDA.
EV / Revenue (LTM)
Tonix Pharmaceuticals Financial Valuation Multiples
As of March 18, 2026, Tonix Pharmaceuticals has market cap of $179M.
Equity research analysts estimate Tonix Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Tonix Pharmaceuticals has a P/E ratio of (1.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $179M | XXX | $179M | XXX | XXX | XXX |
| EV (current) | ($11M) | XXX | ($11M) | XXX | XXX | XXX |
| EV/Revenue | (0.5x) | XXX | (1.1x) | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 0.2x | XXX | XXX | XXX |
| EV/EBIT | 0.1x | XXX | 0.1x | XXX | XXX | XXX |
| EV/Gross Profit | (0.7x) | XXX | (4.7x) | XXX | XXX | XXX |
| P/E | (1.5x) | XXX | (1.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 0.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Tonix Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Tonix Pharmaceuticals Margins & Growth Rates
Tonix Pharmaceuticals' revenue in the last 12 month grew by 213%.
Tonix Pharmaceuticals' revenue per employee in the last FY averaged $0.3M.
Tonix Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 213% | XXX | 30% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (711%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (37%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 405% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 200% | XXX | 396% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 768% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Tonix Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Cartesian Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| EQL Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Sagimet Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| BioVersys | XXX | XXX | XXX | XXX | XXX | XXX |
| PhotoCure | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Tonix Pharmaceuticals M&A Activity
Tonix Pharmaceuticals acquired XXX companies to date.
Last acquisition by Tonix Pharmaceuticals was on XXXXXXXX, XXXXX. Tonix Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Tonix Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialTonix Pharmaceuticals Investment Activity
Tonix Pharmaceuticals invested in XXX companies to date.
Tonix Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Tonix Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Tonix Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Tonix Pharmaceuticals
| When was Tonix Pharmaceuticals founded? | Tonix Pharmaceuticals was founded in 2007. |
| Where is Tonix Pharmaceuticals headquartered? | Tonix Pharmaceuticals is headquartered in United States. |
| How many employees does Tonix Pharmaceuticals have? | As of today, Tonix Pharmaceuticals has over 81 employees. |
| Who is the CEO of Tonix Pharmaceuticals? | Tonix Pharmaceuticals' CEO is Seth Lederman. |
| Is Tonix Pharmaceuticals publicly listed? | Yes, Tonix Pharmaceuticals is a public company listed on Nasdaq. |
| What is the stock symbol of Tonix Pharmaceuticals? | Tonix Pharmaceuticals trades under TNXP ticker. |
| When did Tonix Pharmaceuticals go public? | Tonix Pharmaceuticals went public in 2009. |
| Who are competitors of Tonix Pharmaceuticals? | Tonix Pharmaceuticals main competitors are Cartesian Therapeutics, EQL Pharma, Sagimet Biosciences, BioVersys. |
| What is the current market cap of Tonix Pharmaceuticals? | Tonix Pharmaceuticals' current market cap is $179M. |
| What is the current revenue of Tonix Pharmaceuticals? | Tonix Pharmaceuticals' last 12 months revenue is $23M. |
| What is the current revenue growth of Tonix Pharmaceuticals? | Tonix Pharmaceuticals revenue growth (NTM/LTM) is 213%. |
| What is the current EV/Revenue multiple of Tonix Pharmaceuticals? | Current revenue multiple of Tonix Pharmaceuticals is (0.5x). |
| Is Tonix Pharmaceuticals profitable? | No, Tonix Pharmaceuticals is not profitable. |
| What is the current net income of Tonix Pharmaceuticals? | Tonix Pharmaceuticals' last 12 months net income is ($120M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.